Clinical Report: Forecasting Remission in Membranous Nephropathy
Overview
This study evaluates the predictive value of early dynamic biomarkers in membranous nephropathy (MN) for 12-month remission. A nomogram was developed based on changes in anti-PLA2R antibody titers, urine protein, and serum albumin levels.
Background
Membranous nephropathy is a leading cause of nephrotic syndrome in adults, often leading to significant morbidity. Early identification of patients at risk for poor outcomes is important. Traditional prognostic methods rely on static indicators.
Data Highlights
Biomarker
Remission (n=86)
Non-Remission (n=58)
p-value
Anti-PLA2R Antibody Decline (%)
85.74
47.26
< 0.001
24-h Urine Protein Reduction (%)
42.5
4.5
< 0.001
Serum Albumin Increase (%)
17.06
6.47
< 0.001
Key Findings
Dynamic changes in anti-PLA2R antibodies, urinary protein, and serum albumin at 1 month post-treatment are effective predictors of 12-month remission in MN.
Non-remission patients showed significantly lower declines in anti-PLA2R antibodies and urinary protein, and smaller increases in serum albumin compared to remission patients.
1-month urinary protein, anti-PLA2R decline, and albumin increase were identified as independent predictors of remission.
The nomogram model demonstrated excellent discrimination (AUC = 0.905) and strong calibration.
Clinical Implications
The nomogram developed in this study can assist clinicians in early risk stratification for patients with membranous nephropathy.
Conclusion
Early monitoring of specific biomarkers can enhance the prediction of remission in membranous nephropathy.
